Analgesia aNd caNcer recUrrence Lung cAncer Resection
Impact of Analgesia on Cancer Recurrence and Mortality Within Five Years After Stage I Non-Small Cell Lung Cancer Resection
1 other identifier
observational
382
1 country
1
Brief Summary
The choice of analgesia after cancer surgery may play a role in the onset of recurrence, particularly opioids seem to play a role in the immune system by promoting cancer cell proliferation and migration. Based on this consideration, our aim was to assess the impact of perioperative analgesia's choice on cancer recurrence after curative surgery for Stage I Non-Small Cell Lung Cancer. The investigators retrospectively reviewed the records of patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012. Patients received analgesia either by peridural (PERI group) or, in case of patient refusal or failure in catheter positioning, intravenous analgesia with opioids (EV group). Follow-up was concluded in August 2019. The five-year cumulative incidence of recurrence and the overall survival were evaluated and adjusted with a propensity score matching methodology.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 17, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2020
CompletedFirst Submitted
Initial submission to the registry
November 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2020
CompletedFirst Posted
Study publicly available on registry
December 7, 2020
CompletedDecember 21, 2020
December 1, 2020
1.3 years
November 30, 2020
December 18, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
cumulative incidence of recurrence and the overall survival
5 years
Study Arms (2)
PERI group
EV group
Interventions
We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.
Eligibility Criteria
Patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012
You may qualify if:
- Age ≥ 18 yrs
- Patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012
You may not qualify if:
- Age\<18aa
- Pregnancy
- Day hospital patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
AOU Città della Salute e della Scienza di Torino
Torino, 10100, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Luca Brazzi, Professor
University of Torino
- PRINCIPAL INVESTIGATOR
Giulio L Rosboch, MD
A.O.U. Città della Salute e della Scienza
- STUDY DIRECTOR
Ilaria De Domenici, MD
University of Torino
- PRINCIPAL INVESTIGATOR
Edoardo Ceraolo, MD
A.O.U. Città della Salute e della Scienza
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
November 30, 2020
First Posted
December 7, 2020
Study Start
December 17, 2018
Primary Completion
April 1, 2020
Study Completion
November 30, 2020
Last Updated
December 21, 2020
Record last verified: 2020-12